UNION therapeutics

Executive Summary

UNION therapeutics is a privately held, clinical-stage pharmaceutical company headquartered in Hellerup, Denmark, dedicated to developing novel small-molecule therapies in immunology—a large and rapidly growing therapeutic area. Founded in 2017, the company is led by an international team of biotech entrepreneurs and seasoned pharma executives with a proven track record of bringing more than fifteen drugs to market. UNION's pipeline focuses on addressing significant unmet needs in inflammatory and immune-mediated diseases, leveraging deep expertise in immunology and drug development. The company is currently advancing multiple programs through Phase 2 clinical trials, positioning itself for key value inflection points in the near term. As a Phase 2 company, UNION's near-term value drivers center around clinical data readouts from its lead programs, potential strategic partnerships to accelerate development and commercialization, and financing to support ongoing trials. The company's private status limits public disclosure, but its experienced leadership and focus on high-demand therapeutic areas suggest strong potential. Upcoming catalysts include the release of Phase 2 efficacy and safety data for its lead immunology candidate, which could validate the platform and support further investment or partnership interest. Additionally, the company may pursue a Series C financing round to fund later-stage trials, or secure a licensing deal with a larger pharmaceutical partner. These events, if successful, could significantly enhance UNION's valuation and pipeline prospects.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 clinical data for lead immunology candidate60% success
• Q4 2026Potential strategic partnership or licensing deal50% success
• Q1 2027Series C financing round70% success